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SUMMARY
A man in his late 30s developed non-ischaemic
cardiomyopathy due to systemic cobalt toxicity
associated with accelerated bearing surface wear from
metal-on-metal hip resurfacing implanted in the previous
6 years. Following revision arthroplasty, the patient
regained baseline cardiac function. Cobalt-induced
cardiomyopathy is a grave condition that deserves early
consideration due to potentially irreversible morbidity.
We present this case to increase awareness, facilitate
early detection and emphasise the need for research into
the diagnosis and management of at-risk patients.

BACKGROUND
The Birmingham hip resurfacing (BHR, Smith and
Nephew, Memphis, Tennessee, USA) has reported
implant survival rates of 98% at 15 years.1 This
contrasts most metal-
on-
metal total hip arthroplasties that have been removed from the market
due to local and systemic complications.2–5 While
the use of metal-
on-
metal arthroplasty components is minimal in current practice, many patients
with existing implants are at risk of severe sequela,
including cardiovascular disease. We present a case
of non-ischaemic cardiomyopathy due to systemic
cobalt toxicity from BHR implant wear to aide in
understanding the pathophysiology and diagnosis
of this comorbid condition.
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Figure 1 (A) Six-week postoperative and (B) prerevision
(7 years after index surgery) left hip anteroposterior
radiographs. There was no evidence of implant loosening
or migration on the prerevision radiographs compared
with the initial postoperative films. CT scan prior to
revision surgery measured 51° acetabular inclination and
48° acetabular anteversion.

Figure 2 Patchy, dark staining of the cancellous
bone was observed after removal of the resurfacing
component.

CASE PRESENTATION

A man in his early 30s with history of left hip septic
arthritis, treated 3 years previously with surgical
debridement and antibiotics, presented to the senior
author’s clinic complaining of left hip pain. On
exam, the patient had limited motion. Radiographs
demonstrated bone-
on-
bone arthritis, and infectious workup was negative. Due to the patient’s
age, he opted for BHR. A couple of months later,
the BHR was completed using size 52 cup and 44
femoral head, with a routine perioperative course.
Six years later, the patient presented to the emergency department with shortness of breath. Workup
showed a severely reduced left ventricular ejection
fraction (EF) of 25% and large pericardial effusion.
Cardiac catheterisation ruled out cardiac ischaemia
and pericardiocentesis yielded transudate. The
patient was stabilised and discharged on diuretics
and beta blockers with a diagnosis of non-specific
cardiomyopathy. His symptoms improved over the
next 2 months and repeat echocardiogram showed
an EF of 60%. However, several months later, he
returned to the cardiologist for shortness of breath.
Inotropes were prescribed. Four months later, he
was admitted for acute cardiac decompensation.
His EF was 30%.

INVESTIGATIONS

At the time of the patient’s acute cardiac decompensation, autoimmune and infectious workups for
non-ischaemic cardiomyopathy were negative. The
patient was stabilised with intravenous inotropes.
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Figure 3 Optical coordinate measuring machine heat maps of the
femoral head (A) and acetabular liner (B) bearing surfaces show
primary and secondary wear scars with corresponding volumetric wear
penetration, indicative of edge loading. Illustration and model were
completed by DJH and RP.

Given the atypical clinical presentation, cardiology considered
metal-induced cardiotoxicity and ordered specific metal labs.
Serum cobalt was significantly elevated at 178.7 ng/mL and
a repeat confirmatory lab was 141.8 ng/mL (normal <1.0 ng/
mL; ARUP Laboratories, Salt Lake City, Utah, USA). Worsening
cardiac function prompted admission to the cardiac critical care
unit and chelation was initiated with acetylcysteine. Within
72 hours of chelation, serum cobalt decreased to 38.1 ng/mL.
Myocardial biopsy performed at this time showed interstitial
fibrosis and vacuolar changes consistent with prior reports of
cobalt-associated cardiomyopathy.6 7

TREATMENT

Orthopaedics was consulted for evaluation of the BHR. The
patient was medically optimised for revision surgery with
2 weeks of acetylcysteine. Prerevision radiographs showed no
implant loosening (figure 1). CT of the abdomen/pelvis demonstrated an acetabular component with 51° of inclination and 48°
of anteversion. Ultrasound and MRI showed an intra-articular
effusion that communicated with the iliopsoas bursa.
Intraoperatively, after making the arthrotomy, there was
straw-coloured synovial fluid with no signs of infection. The
acetabular and femoral components were both well fixed. On
implant removal, patchy areas of black-stained cancellous bone
were noted (figure 2). The hip was successfully revised to a
ceramic-on-polyethylene total hip arthroplasty.

Figure 5 (A) The joint pseudocapsule was dominated by a marked
macrophage response. The synovial surface (at right) was replaced by an
organising fibrin exudate. (B) Greyish, particle-laden macrophages were
seen throughout the tissue. Larger, dark particles were discernible within
the cytoplasm. A few scattered plasma cells are also present. (H&E; A,
×20; B, ×400).

OUTCOME AND FOLLOW-UP

Postoperatively, echocardiography showed an EF of 30% on
intravenous inotropes, and serum cobalt level was 63.1 ng/mL.
Two months after surgery, the patient’s EF was 49% and the
patient reported he was back to his functional baseline. The
patient was gradually weaned off intravenous cardiac inotropes
over the next 2 months and was transitioned to only taking oral
medications. By 4 months postoperatively, his serum cobalt level
had decreased to 4 ng/mL. Two years after revision surgery, the
patient continues to take maintenance oral cardiac medications
and regularly follows up with his cardiologist. He has sustained
normal cardiac function on follow-up echocardiograms. At the
time of writing, the patient is alive and continues to functionally
improve.

Retrieval analysis
Methodology

Both head and liner were measured with an optical coordinate-
measuring machine (OrthoLux, RedLux) for three-dimensional
reconstruction of the original bearing surface and computation of volumetric wear. Bearing surfaces were also viewed in a
scanning electron microscope (SEM) to examine wear features.

Figure 4 (A) Backscattered scanning electron microscope image
of the CoCrMo femoral head bearing surface with a large chatter
mark (trail left behind by hard particles trapped between the bearing
surfaces) and indents indicating abrasive third body wear. Mixed hard
phases (arrow) are also seen on the surface. (B) Embedded carbide
particles within the surface of the femoral head.

Figure 6 (A) High-power micrograph of particle-laden macrophages
within the joint pseudocapsule. A few large particles are also visible
(arrows) (H&E, ×600). (B) Backscattered scanning electron microscope
image of a comparable area in an adjacent section to (A), showing
densely packed macrophages. Two large (7.11 and 6.57 µm) extracellular
particles are also present as denoted by the arrows along the long axis
of the particles (×2200). (C) EDS elemental maps of the area outlined in
(B) demonstrate that the intracellular particles within the macrophages
are chromium phosphate and the two extracellular particles are CoCrMo
alloy. EDS, energy-dispersive x-ray spectroscopy.
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Figure 7 (A) Cardiac biopsy adjacent to tissue samples shown in (B)
and (C) (H&E, ×40). (B) FTIR-I heat map imaged at the amide III-specific
wavenumber (1236/cm) showing abnormal collagen expansion and
confirming interstitial fibrosis. (C) FTIR-I heat map imaged at 1026/cm,
indicating granular glycogen deposition. FTIR, Fourier transform infrared
spectroscopy.

Tissue analysis was performed on joint pseudocapsule and heart
biopsy tissues. Tissue samples were assessed via light microscopy
for histopathological analysis of H&E-
stained sections, SEM
analysis (JEOL, IT500HR-
LV) with energy-
dispersive x-
ray
spectroscopy (EDS, Oxford Instruments) for localisation of wear
debris within tissue and chemical mapping and quantification
of implant metals, and Fourier transform infrared spectroscopy
(FTIR) for chemical analysis of periprosthetic and cardiac tissue.8

RESULTS

Wear features on head and liner were consistent with edge
loading (figure 3). SEM analysis revealed multiple grooves and
scratches, indicating the acting wear mechanism was abrasion.
Additionally, previously described mixed-coarse hard phases—
characteristic for as-cast cobalt-chromium-molybdenum alloy—
within the alloy had fractured from the surface (figure 4).9
The total wear volume was 168.5 mm3 (head: 46.3 mm3, cup:
122.2 mm3), resulting in a wear rate of 24.4 mm3/year (head:
6.7 mm3/year, cup: 17.7 mm3/year).
The joint pseudocapsule tissue was dominated by a marked
macrophage response (figure 5), with only mild to moderate
perivascular infiltrate of lymphocytes and plasma cells. Diffuse
lymphocytes and plasma cells were also mildly present. The
macrophages throughout the tissue were laden with greyish
particles. Formations of particle-
induced granulomas with
necrosis were also observed. The synovial surface consisted of

Table 1

Figure 8 (A) Cardiac biopsy section adjacent to tissue samples
shown in (B) and (C) (H&E, ×100). (B) Backscattered scanning electron
microscope image of biopsy tissue (×1500). (C) Higher magnification
of area outlined in B (×17 000) showing a 448 nm particle in the tissue.
(D) EDS elemental maps of the area outlined in (C) demonstrates the
particle to be CoCrMo alloy. (E) Quantitation of the corresponding EDS
spectrum of the particle shows the elemental composition percentages
of CO, Cr and Mo to be similar to the percentages seen in the implant
alloy. EDS, energy-dispersive x-ray spectroscopy.
fibrin exudates with some areas organising and containing dense
particle-laden macrophages.
The SEM/EDS analysis of the pseudocapsule revealed large,
mostly extracellular CoCrMo particles ranging in size from 1 µm
to 7 µm (figure 6). Intracellularly, mostly chromium phosphate
was observed as indicated by EDS mapping and confirmed by a
strong characteristic phosphate (ν(PO43−): 1200–900/cm) absorbance peak in their infrared spectra.10 FTIR univariate imaging
of cardiac tissue demonstrated interstitial fibrosis and glycogen
deposition (figure 7), which are hallmarks of cardiomyopathy
pathology described by Mathlouthi and Koenig and Colagar et
al.11 12 Surprisingly, CoCrMo particles ranging in size from 0.16
μm to 15.9 μm were found within the heart tissue (figure 8).
Eighteen particles were found within two sections of the same
biopsy sample. No direct association of macrophages or other
cell types with CoCrMo particles was observed.

DISCUSSION

This case demonstrates a rare, systemic complication of metal-on-
metal hip replacement/resurfacing. Cobalt-induced cardiomyopathy secondary to metal-on-metal hip arthroplasty/resurfacing is
an increasingly investigated complication in the literature, but
most of these cases are associated with total hip arthroplasty

Summary of select cases illustrating non-ischaemic cardiomyopathy in patients with metal-on-metal hip replacements
Patient presentation

Maximal cobalt
(ng/mL)

Case

Demographic

Cardiac function

Intervention

Sequelae

114

49-year-old man with
2 years after revision due to hip
MoM Articular Surface
pain, tinnitus, neuropathy
Replacement System (DePuy)

83

Diastolic dysfunction noted
on echocardiogram

Hip joint revision surgery

Not documented

215

58-year-old rural woman
with right MoM resurfacing
system

10 years after arthroplasty with
symptoms of heart failure

169

NYHA class III non-
ischaemic dilated
cardiomyopathy

Right hip revision with
evidence of metallosis and
osteolysis

Improved echocardiogram
measures

321

46-year-old Caucasian man
with bilateral MoM THA
(ZimmerBiomet)

3 years after arthroplasty with
dyspnoea, ascites; evaluated for
cobalt toxicity 6 years later

156

EF=20%

LVAD placement and then
bilateral hip revision with
evidence of metallosis.
Excessive anteversion noted.

Recovered EF to 38%

422

69-year-old woman with
bilateral MoM THA (DePuy)

2 years after arthroplasty with
hip pain

192

EF=10%–15%

Bilateral hip revision with
evidence of metallosis

Death from haemorrhagic
stroke 7 days post-revision

57

54-year-old man with
bilateral MoM THA (Biomet)

Symptoms of heart failure

189

Left ventricular dysfunction Revision of bilateral hips
noted on echocardiogram
and cardiac MRI

Lack of improvement with
permanent myocardial
damage

EF, ejection fraction; LVAD, left ventricular assistance device; MoM, metal on metal; NYHA, New York Heart Association; THA, total hip arthroplasty.
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instead of hip resurfacing.6 13 Two prior cases of cardiomyopathy
associated with hip resurfacing and elevated cobalt levels have
been reported, and in both cases, cardiac function improved
after revision arthroplasty.14 15 In both instances, retrieval analysis demonstrated acetabular component edge loading. Neither
of these previous cases provided a detailed analysis of the wear
pattern or volume, and therefore quantitative comparisons
were not possible. Our analysis revealed that the BHR had a
malaligned acetabular component with excessive inclination and

Patient’s perspective
My story started back in -censored year- when I had injured my
finger doing construction work. My finger ultimately got infected
and the infection spread through my blood to my hip, which
destroyed all my cartilage. My wife, who worked in our local
healthcare system, referred me to my orthopedic surgeon who
gave me the option of hip resurfacing, while many others had no
attractive solutions since I was so young. I was not able to even
walk at this point and decided to proceed with the resurfacing
surgery.
I honestly did not have any problems with my hip after the
first surgery aside from some muscle tightness since I had not
walked normally for 2 years before my hip resurfacing. I had no
pain or mobility issues.
Eventually, I started having trouble with getting around and
I could not even go up and down the stairs without shortness
of breath. My wife knew that something serious was happening
since she worked in the cardiology department. She got me
set up with my cardiologist and things just started to escalate.
When I was initially put on medications, I started to feel better.
However, a couple months later, things became significantly
worse. For a whole year, it was unclear what was happening. I
was terrified because I was so young and did not know what
was happening. I did not want to leave my young children so
early in life. Not once during that year did I think that the issue
was ultimately my hip.
At the beginning of -c ensored year- after being on IV heart
medications and multiple cardiac catheterizations, did we
consider there may be an issue with metal toxicity from my hip.
When I had heard that the problem may be coming from my hip,
I had gotten a feeling of relief; that I could be treated and feel
better. I went into my revision surgery hopeful, despite how sick
I was at that time. Two months after the surgery, I was getting
back to normal. I was able to go on vacation with my family and
even walk 15 miles in a day without much issue.
Fast forwarding to today, I am now able to do things without
limitations; I am able to go biking with my kids and go hiking
with my family. I have no issues with my hip and do not
experience shortness of breath. In fact, my mobility with my hip
is even better than before. I still have to take oral medications for
my heart, but I continue to improve and am grateful.
There is nothing I think the medical providers could have
done differently. It came down to getting the metal out of me
and getting on the right medications. My biggest supporter was
my wife throughout this process. I believe that my condition
often goes underdiagnosed because many patients with metal
hips are older and heart failure is common, therefore there is
no consideration of heavy metal toxicity. I think this problem is
more prominent than we think. I hope no one has to go through
something like me and I hope this research provides clarification
for other doctors and patients.
4

Learning points
► Cobalt toxicity-induced cardiomyopathy is a rare but grave

complication following metal-on-metal total hip resurfacing.

► Hip arthroplasty component malpositioning may increase

the risk of cobalt toxicity in the context of metal-on-metal
bearing surfaces due to altered wear mechanics.
► Cellular responses and systemic transport of metal
alloy particles likely play a critical role in cobalt-induced
cardiotoxicity.
► Prompt consideration and diagnosis of a metal-induced
cardiomyopathy in at-risk patients can allow for early
chelation and revision surgery to non-metal-on-metal hip
replacement components, ultimately preventing irreversible
cardiac damage.

anteversion, which subsequently may have produced high wear
due to edge loading. Based on normal wear rates determined by
Koper et al (head: <1 mm3/year, cup: <1 mm3/year), our patient
had 6× and 17× normal head and cup wear rates, respectively.16 Gill and Pourzal et al have described that edge loading
causes a shift in wear mechanism from mild surface fatigue to
severe abrasion.17 18 Under these abrasive conditions, larger
wear particles (100 nm to 2 µm) are generated that maintain the
alloy composition of CoCrMo, whereas during surface fatigue,
smaller particles (<100 nm) mostly consisting of chromium
oxide are generated.19 Therefore, the finding of large particles
within the periprosthetic tissue is consistent with edge loading.
EDS and FTIR analysis further suggest that macrophages alter
these particles chemically through phagocytosis, resulting in
chromium–phosphate as the primary corrosion product. Interestingly, CoCrMo alloy particles were also found within cardiac
tissue. The particles having the exact elemental composition as
the alloy suggests that these particles were not yet phagocytosed
by macrophages prior to transport to the heart. Larger CoCrMo
particles are likely to corrode slowly due to protective surface
passivation. However, in the capsular tissue, we observed that
phagocytosis is associated with CrPO4, which may also result in
the release of ionic Co. While we observed numerous particles
within the cardiac biopsy, we were not able to identify any interaction with resident macrophages. However, if particles within
the heart were phagocytosed by macrophages, the result may
be a high local concentration of Co which, coupled with high
circulating levels of blood Co, may potentiate a cardiomyopathy.
A literature review of cardiomyopathy cases associated with
metal-
on-
metal hip arthroplasty showed that some patients
presented with hip symptoms, while others had isolated cardiomyopathy (table 1). Patients in these cases differed in the extent
of cobalt toxicity, with cobalt levels ranging from 83 ng/mL to
192 ng/mL. While all patients in the cases underwent revision
to non-metal-on-metal bearing reconstructions, outcomes varied
with permanent myocardial damage and subsequent death
in some cases but improved cardiac function in others. Some
authors have argued that systemic complications typically occur
at cobalt levels of >100 ng/mL and are most likely once concentrations reach 300 ng/mL.6 20 However, given our patient had
serum cobalt levels less than 300 ng/mL, it is evident blood cobalt
levels must be considered with patient-specific risk factors, clinical presentation and analysis of periarticular and cardiac tissue.
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